Limits...
Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7.

Park SO, Yoo YB, Kim YH, Baek KJ, Yang JH, Choi PC, Lee JH, Lee KR, Park KS - Ann Surg Treat Res (2015)

Bottom Line: In the MDA-MB-231 cells, the combination therapy group (docetaxel at 500pM plus selenium at 10µM) showed a significantly decreased percentage of cell growth (15% vs. 28%; P = 0.004), a significantly increased percentage of late apoptosis (63% vs. 26%; P = 0.001), and an increased cell cycle arrest in the G2/M phase (P = 0.001) compared with the solitary docetaxel therapy group.Isobologram analysis demonstrated the synergistic effect of the combination therapy in the MDA-MB-231 cells.However, in the MCF-7 cells, no significant differences in the percentage of cell growth apoptosis, the percentage of apoptosis, and the pattern of cell cycle arrest were noted between the combination therapy groups and the solitary docetaxel therapy group.

View Article: PubMed Central - PubMed

Affiliation: Department of Emergency Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT

Purpose: The anticancer property and cytoprotective role of selenium in chemotherapy have been reported. However, the combination effects of selenium on chemotherapy for advanced breast cancer have not yet been clearly defined. The purpose of this study was to investigate the combined effects of selenium on chemotherapy using docetaxel on breast cancer cell lines.

Methods: Under adherent culture conditions, two breast cancer cell lines, MDA-MB-231 and MCF-7, were treated with docetaxel at 500pM and selenium at 100nM, 1µM, or 10µM. Changes in cell growth, cell cycle duration, and degree of apoptosis after 72 hours in each treated group were evaluated.

Results: In the MDA-MB-231 cells, the combination therapy group (docetaxel at 500pM plus selenium at 10µM) showed a significantly decreased percentage of cell growth (15% vs. 28%; P = 0.004), a significantly increased percentage of late apoptosis (63% vs. 26%; P = 0.001), and an increased cell cycle arrest in the G2/M phase (P = 0.001) compared with the solitary docetaxel therapy group. Isobologram analysis demonstrated the synergistic effect of the combination therapy in the MDA-MB-231 cells. However, in the MCF-7 cells, no significant differences in the percentage of cell growth apoptosis, the percentage of apoptosis, and the pattern of cell cycle arrest were noted between the combination therapy groups and the solitary docetaxel therapy group.

Conclusion: Our in vitro study indicated that the combination of selenium with docetaxel inhibits cell proliferation through apoptosis and cell arrest in the G2/M phase in MDA-MB-231 breast cancer cells.

No MeSH data available.


Related in: MedlinePlus

Apoptosis after combined treatment with docetaxel at 500pM and selenium at 100nM, 1µM, or 10µM in the MDA-MB-231 cell line (A) and the MCF-7 cell line (B). All cells were stained with fluorescein isothiocyanate (FITC) conjugated Annexin V in a buffer containing propidium iodide and were analyzed using flow cytometry. For each treatment, the percentage of viable cells is shown in the lower left quadrant, for which both Annexin V and propidium iodide levels are low. Data from a representative experiment (from a total of three) are shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4325646&req=5

Figure 3: Apoptosis after combined treatment with docetaxel at 500pM and selenium at 100nM, 1µM, or 10µM in the MDA-MB-231 cell line (A) and the MCF-7 cell line (B). All cells were stained with fluorescein isothiocyanate (FITC) conjugated Annexin V in a buffer containing propidium iodide and were analyzed using flow cytometry. For each treatment, the percentage of viable cells is shown in the lower left quadrant, for which both Annexin V and propidium iodide levels are low. Data from a representative experiment (from a total of three) are shown.

Mentions: In the MDA-MB-231 cell lines, early apoptosis in all combined therapy groups was not significantly different from the DT 500pM group (13%-15% vs. 18%, P = 0.125). However, late apoptosis increased in the DT 500pM + SN 10µM compared with the DT 500pM and other combination therapy groups (63% vs. 29%-36%) (Fig. 3). Cell cycle analysis indicated a dominant increase in cell cycle arrest in the G2/M phase in the DT 500pM + SN 10µM groups compared with the other treatment groups (Fig. 4).


Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7.

Park SO, Yoo YB, Kim YH, Baek KJ, Yang JH, Choi PC, Lee JH, Lee KR, Park KS - Ann Surg Treat Res (2015)

Apoptosis after combined treatment with docetaxel at 500pM and selenium at 100nM, 1µM, or 10µM in the MDA-MB-231 cell line (A) and the MCF-7 cell line (B). All cells were stained with fluorescein isothiocyanate (FITC) conjugated Annexin V in a buffer containing propidium iodide and were analyzed using flow cytometry. For each treatment, the percentage of viable cells is shown in the lower left quadrant, for which both Annexin V and propidium iodide levels are low. Data from a representative experiment (from a total of three) are shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4325646&req=5

Figure 3: Apoptosis after combined treatment with docetaxel at 500pM and selenium at 100nM, 1µM, or 10µM in the MDA-MB-231 cell line (A) and the MCF-7 cell line (B). All cells were stained with fluorescein isothiocyanate (FITC) conjugated Annexin V in a buffer containing propidium iodide and were analyzed using flow cytometry. For each treatment, the percentage of viable cells is shown in the lower left quadrant, for which both Annexin V and propidium iodide levels are low. Data from a representative experiment (from a total of three) are shown.
Mentions: In the MDA-MB-231 cell lines, early apoptosis in all combined therapy groups was not significantly different from the DT 500pM group (13%-15% vs. 18%, P = 0.125). However, late apoptosis increased in the DT 500pM + SN 10µM compared with the DT 500pM and other combination therapy groups (63% vs. 29%-36%) (Fig. 3). Cell cycle analysis indicated a dominant increase in cell cycle arrest in the G2/M phase in the DT 500pM + SN 10µM groups compared with the other treatment groups (Fig. 4).

Bottom Line: In the MDA-MB-231 cells, the combination therapy group (docetaxel at 500pM plus selenium at 10µM) showed a significantly decreased percentage of cell growth (15% vs. 28%; P = 0.004), a significantly increased percentage of late apoptosis (63% vs. 26%; P = 0.001), and an increased cell cycle arrest in the G2/M phase (P = 0.001) compared with the solitary docetaxel therapy group.Isobologram analysis demonstrated the synergistic effect of the combination therapy in the MDA-MB-231 cells.However, in the MCF-7 cells, no significant differences in the percentage of cell growth apoptosis, the percentage of apoptosis, and the pattern of cell cycle arrest were noted between the combination therapy groups and the solitary docetaxel therapy group.

View Article: PubMed Central - PubMed

Affiliation: Department of Emergency Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT

Purpose: The anticancer property and cytoprotective role of selenium in chemotherapy have been reported. However, the combination effects of selenium on chemotherapy for advanced breast cancer have not yet been clearly defined. The purpose of this study was to investigate the combined effects of selenium on chemotherapy using docetaxel on breast cancer cell lines.

Methods: Under adherent culture conditions, two breast cancer cell lines, MDA-MB-231 and MCF-7, were treated with docetaxel at 500pM and selenium at 100nM, 1µM, or 10µM. Changes in cell growth, cell cycle duration, and degree of apoptosis after 72 hours in each treated group were evaluated.

Results: In the MDA-MB-231 cells, the combination therapy group (docetaxel at 500pM plus selenium at 10µM) showed a significantly decreased percentage of cell growth (15% vs. 28%; P = 0.004), a significantly increased percentage of late apoptosis (63% vs. 26%; P = 0.001), and an increased cell cycle arrest in the G2/M phase (P = 0.001) compared with the solitary docetaxel therapy group. Isobologram analysis demonstrated the synergistic effect of the combination therapy in the MDA-MB-231 cells. However, in the MCF-7 cells, no significant differences in the percentage of cell growth apoptosis, the percentage of apoptosis, and the pattern of cell cycle arrest were noted between the combination therapy groups and the solitary docetaxel therapy group.

Conclusion: Our in vitro study indicated that the combination of selenium with docetaxel inhibits cell proliferation through apoptosis and cell arrest in the G2/M phase in MDA-MB-231 breast cancer cells.

No MeSH data available.


Related in: MedlinePlus